Alzheimer's disease (AD) in multiple sclerosis (MS): A systematic review of published cases, mechanistic links between AD and MS, and possible clinical evaluation of AD in MS.

IF 2.8 Q2 NEUROSCIENCES
Journal of Alzheimer's disease reports Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI:10.1177/25424823251316134
Ross Cottrill, Anupa Ekanayake, Cooper Grove, Senal Peiris, Nicholas Corbett, Biyar Ahmed, Will Jens, Tim Brearly, Sangam Kanekar, Paul Eslinger, Qing Yang, Prasanna Karunanayaka
{"title":"Alzheimer's disease (AD) in multiple sclerosis (MS): A systematic review of published cases, mechanistic links between AD and MS, and possible clinical evaluation of AD in MS.","authors":"Ross Cottrill, Anupa Ekanayake, Cooper Grove, Senal Peiris, Nicholas Corbett, Biyar Ahmed, Will Jens, Tim Brearly, Sangam Kanekar, Paul Eslinger, Qing Yang, Prasanna Karunanayaka","doi":"10.1177/25424823251316134","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Alzheimer's disease (AD) and multiple sclerosis (MS) are two neurological disorders that can pose enormous burden to a person's quality of life. Due to new therapeutic advancements that significantly extend the lifespan, there may be an increased prevalence of AD in elderly MS patients. <b>Objective:</b> Building on a previous review on MS-AD coexistence, this review not only aimed to broaden the pool of literature searched, but also investigated possible mechanistic links between clinical markers for MS and AD. <b>Methods:</b> We searched for newly reported cases of coexisting MS and AD in PubMed, Clinical Key, BioMed Central, and Europe PubMed Central databases; and identified 101 new cases in addition to the previously reported 24 cases by Luczynski et al. (2019). The resulting 125 comorbid cases necessitated an evaluation of literature on the pathogenesis of MS and AD. <b>Results:</b> This review highlights many overlaps between AD and MS (for instance, the immune cell dysfunction, glymphatic dysfunction, genetics, environmental factors, and others). We critically evaluated clinical and laboratory metrics used to identify AD in MS patients (e.g., MRI, amyloid-β and tau protein identification, miRNA biomarker evaluation, cerebrospinal fluid analysis, vitamin levels, gut microbiota etc.). <b>Conclusions:</b> Future research should refine these diagnostic criteria and focus on enhancing screening and detection methods for AD in MS patients. Furthermore, one should also investigate the primary causes of the increased comorbidity between AD and MS.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"9 ","pages":"25424823251316134"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864252/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25424823251316134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Alzheimer's disease (AD) and multiple sclerosis (MS) are two neurological disorders that can pose enormous burden to a person's quality of life. Due to new therapeutic advancements that significantly extend the lifespan, there may be an increased prevalence of AD in elderly MS patients. Objective: Building on a previous review on MS-AD coexistence, this review not only aimed to broaden the pool of literature searched, but also investigated possible mechanistic links between clinical markers for MS and AD. Methods: We searched for newly reported cases of coexisting MS and AD in PubMed, Clinical Key, BioMed Central, and Europe PubMed Central databases; and identified 101 new cases in addition to the previously reported 24 cases by Luczynski et al. (2019). The resulting 125 comorbid cases necessitated an evaluation of literature on the pathogenesis of MS and AD. Results: This review highlights many overlaps between AD and MS (for instance, the immune cell dysfunction, glymphatic dysfunction, genetics, environmental factors, and others). We critically evaluated clinical and laboratory metrics used to identify AD in MS patients (e.g., MRI, amyloid-β and tau protein identification, miRNA biomarker evaluation, cerebrospinal fluid analysis, vitamin levels, gut microbiota etc.). Conclusions: Future research should refine these diagnostic criteria and focus on enhancing screening and detection methods for AD in MS patients. Furthermore, one should also investigate the primary causes of the increased comorbidity between AD and MS.

阿尔茨海默病(AD)合并多发性硬化症(MS):对已发表病例的系统回顾,AD与MS之间的机制联系,以及AD在多发性硬化症中可能的临床评估。
背景:阿尔茨海默病(AD)和多发性硬化症(MS)是两种严重影响患者生活质量的神经系统疾病。由于新的治疗进展显著延长了寿命,老年MS患者中AD的患病率可能会增加。目的:在既往文献综述的基础上,本综述不仅旨在扩大文献检索范围,而且旨在探讨多发性硬化症临床标志物与AD之间可能的机制联系。方法:我们在PubMed、Clinical Key、BioMed Central和european PubMed Central数据库中检索新报道的多发性硬化症和AD并存病例;除了Luczynski等人(2019)先前报告的24例病例外,还发现了101例新病例。由此产生的125例合并症有必要对MS和AD发病机制的文献进行评估。结果:本综述强调了AD和MS之间的许多重叠之处(例如,免疫细胞功能障碍,淋巴功能障碍,遗传,环境因素等)。我们严格评估了用于识别MS患者AD的临床和实验室指标(例如,MRI,淀粉样蛋白-β和tau蛋白鉴定,miRNA生物标志物评估,脑脊液分析,维生素水平,肠道微生物群等)。结论:未来的研究应完善这些诊断标准,重点加强对MS患者AD的筛查和检测方法。此外,人们还应该调查阿尔茨海默病和多发性硬化症合并症增加的主要原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信